Therapeutic Asset Ratings
3,272 results matching 1 filter
91,564
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Tazemetostat
Ovarian Clear Cell Adenocarcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Tazemetostat
Ovarian Endometrioid Adenocarcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Tcr Transduced T-Cells
Malignant Endocrine Neoplasm
National Cancer Institute (NCI)
P2
CCC
(53)
Telaglenastat
Malignant Peripheral Nerve Sheath Tumor
National Cancer Institute (NCI)
P2
CCC
(53)
Tiragolumab
IDH-Wildtype Glioblastoma
National Cancer Institute (NCI)
P2
CCC
(53)
Tirzepatide
Atypical Endometrial Hyperplasia
National Cancer Institute (NCI)
P2
CCC
(53)
Tocilizumab
Diffuse Astrocytoma
National Cancer Institute (NCI)
P2
CCC
(53)
Tocilizumab
Glioblastoma
National Cancer Institute (NCI)
P2
CCC
(53)
Tpst-1495
Classic Familial Adenomatous Polyposis
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Lymphoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Urinary Bladder Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Cervical Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Endometrial Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Carcinoma Of Esophagus
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Gastric Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Head And Neck Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Renal Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Lung Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Uterine Corpus Cancer
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Uterine Cancer
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Ovarian Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Thyroid Gland Carcinoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trametinib
Grade III Glioma
National Cancer Institute (NCI)
P2
CCC
(53)
Trastuzumab
Lymphoma
National Cancer Institute (NCI)
P2
CCC
(53)
Trastuzumab
Carcinoma Of Esophagus
National Cancer Institute (NCI)
P2
CCC
(53)
Showing 2076 to 2100 of 3,272 assets
Previous
Page 84 of 131
Next